Skip to Content

Two years of ADT reduce the risk of metastases in patients undergoing post-prostatectomy radiotherapy

The first results from the RADICALS-HD trial were presented at ESMO22. To reduce the risk of metastasis in patients with prostate cancer undergoing post-prostatectomy radiotherapy, results indicate that two years of androgen deprivation therapy is better than six months. Let Chris Parker, Professor at the Royal Marsden Hospital, UK, explain what impact the results have on the future treatment of prostate cancer.

Chris Parker

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top